| Literature DB >> 29738508 |
Ian W Holloway1,2,3, Robert Bednarczyk4, Vincent L Fenimore5, Cameron Goldbeck6,7, Elizabeth Wu8, Rebecca Himmelstein9, Diane Tan10, Laura Randall11, Chelsea S Lutz12, Paula M Frew13,14,15.
Abstract
We sought to identify the characteristics of men who have sex with men (MSM) who are opinion leaders on immunization issues and to identify potential opportunities to leverage their influence for vaccine promotion within MSM communities. Using venue-based sampling, we recruited and enrolled MSM living in Los Angeles (N = 520) from December 2016 to February 2017 and evaluated characteristic differences in sociodemographic characteristics, health behaviors, and technology use among those classified as opinion leaders versus those who were not. We also asked respondents about their past receipt of meningococcal serogroups A, C, W, and Y (MenACWY) and meningococcal B (MenB) vaccines, as well as their opinions on the importance of 13 additional vaccines. Multivariable results revealed that non-Hispanic black (aOR = 2.64; 95% CI: 1.17⁻5.95) and other race/ethnicity (aOR = 2.98; 95% CI: 1.41⁻6.29) respondents, as well as those with a history of an STI other than HIV (aOR = 1.95; 95% CI: 1.10⁻3.48), were more likely to be opinion leaders. MenACWY (aOR = 1.92; 95% CI: 1.13⁻3.25) and MenB (aOR = 3.09; 95% CI: 1.77⁻5.41) vaccine uptake, and perceived importance for these and seven additional vaccines, were also associated with being an opinion leader. The results suggest that the co-promotion of vaccination and other health promotion initiatives via opinion leaders could be a useful strategy for increasing vaccination among MSM.Entities:
Keywords: MSM; immunization acceptance; immunization assessment; opinion leadership; peer health navigation; vaccine measurement; vaccine promotion
Mesh:
Year: 2018 PMID: 29738508 PMCID: PMC5981978 DOI: 10.3390/ijerph15050939
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Percentages of opinion leadership (yes/no) by sociodemographic, health, and technology use covariates using chi-square significance tests.
| Variable | Non-Opinion Leader | Opinion Leader | Total | |
|---|---|---|---|---|
|
| ||||
| Age (in Years) | 33.1 (32.2, 34.1) | 34.4 (32.3, 36.6) | 33.3 (32.4, 34.1) | 0.33 |
| 18–24 | 21.6 | 11.4 | 20.4 | 0.22 |
| 25–44 | 63.0 | 72.9 | 64.2 | |
| 45–64 | 14.7 | 14.3 | 14.6 | |
| 65+ | 0.7 | 1.4 | 0.8 | |
| Race/Ethnicity | ||||
| White | 36.9 | 26.1 | 35.4 | 0.03 * |
| Black | 14.1 | 21.7 | 15.1 | |
| Hispanic | 33.6 | 26.1 | 32.5 | |
| Other | 15.4 | 26.1 | 17.0 | |
| Education (BA or more) | 50.6 (45.9, 55.2) | 57.1 (45.3, 69.0) | 51.3 (47.0, 55.7) | 0.31 |
| Employed Full-time | 61.7 (57.2, 66.3) | 67.1 (55.9, 78.4) | 62.4 (58.2, 66.5) | 0.39 |
| Income (≥$20,000) | 77.8 (73.9, 81.7) | 87.1 (79.1, 95.2) | 78.9 (75.4, 82.5) | 0.07 |
| Insured | 88.3 (85.3, 91.3) | 88.2 (80.4, 96.1) | 88.3 (85.5, 91.1) | 0.99 |
| Type of Insurance | ||||
| Private | 57.0 | 66.7 | 58.3 | 0.62 |
| Medicaid/Medicare | 25.7 | 15.3 | 24.3 | |
| Other | 5.7 | 6.1 | 5.7 | |
| Resides in West Hollywood | 33.2 (28.8, 37.6) | 40.0 (28.2, 51.8) | 34.0 (30.0, 38.1) | 0.26 |
|
| ||||
| HIV-positive serostatus | 10.6 (7.7, 13.5) | 20.3 (10.6, 30.0) | 11.9 (9.1, 14.7) | 0.02 * |
| Uses Alcohol | 86.9 (83.7, 90.0) | 85.7 (77.3, 94.1) | 86.7 (83.8, 89.7) | 0.79 |
| Uses Marijuana | 50.8 (46.1, 55.4) | 55.7 (43.8, 67.6) | 51.5 (47.2, 55.9) | 0.44 |
| Other Drugs | 47.9 (43.3, 52.5) | 58.6 (46.7, 70.4) | 49.2 (44.9, 53.4) | 0.10 |
| History of STI other than HIV | 45.2 (40.6, 49.8) | 64.3 (52.8, 75.8) | 47.7 (43.4, 52.0) | <0.01 * |
| Sexual Partner | ||||
| Men Only | 90.0 | 88.6 | 89.9 | 0.72 |
| Men and Women | 10.0 | 11.4 | 10.2 | |
| No. Sexual Partners (6 months) | ||||
| 0–5 | 72.7 | 68.6 | 72.2 | 0.77 |
| 6–10 | 13.2 | 15.7 | 13.5 | |
| 11+ | 14.1 | 15.7 | 14.3 | |
| Receptive Condomless Anal Sex | 51.2 (46.6, 55.8) | 57.1 (45.3, 69.0) | 51.9 (47.6, 56.3) | 0.36 |
| High Risk | 65.2 (60.7, 69.8) | 71.2 (60, 82.4) | 65.9 (61.7, 70.1) | 0.34 |
| PrEP Use † | 15.9 (12.2, 19.5) | 29.1 (16.7, 41.5) | 16.0 (12.9, 19.2) | 0.02 * |
| Multi Vitamin | 49.8 (45.1, 54.4) | 61.4 (49.7, 73.1) | 51.3 (46.9, 55.6) | 0.07 |
|
| ||||
| Facebook Usage | 86.6 (83.4, 89.8) | 85.7(77.3, 94.1) | 86.5 (83.5, 89.4) | 0.83 |
| Twitter Usage | 39.9 (35.3, 44.4) | 35.7 (24.2, 47.2) | 39.3 (35.1, 43.5) | 0.51 |
| Daily Email Users | 90.9 (88.2, 93.6) | 92.8 (86.5, 99.0) | 91.2 (88.7, 93.6) | 0.62 |
| Daily Phone Users | 98.9 (97.9, 99.9) | 98.6 (95.7, 100) | 98.9 (97.9, 99.8) | 0.82 |
| Daily Social Media Users | 89.4 (86.4, 92.3) | 95.3 (90, 101) | 90.2 (87.6, 92.8) | 0.14 |
| Used Internet for Vac. Info | 57.6 (53.0, 62.1) | 64.3 (52.8, 75.8) | 58.5 (54.3, 62.7) | 0.29 |
| Used Internet for Vac. Location | 46.2 (41.6, 50.8) | 51.4 (39.4, 63.4) | 46.9 (42.6, 51.2) | 0.42 |
* Indicates significant difference at α = 0.05 level; † Calculated only for those who are HIV negative, N = 396 and 55; Note: Some percentages may not add to 100.0 due to rounding.
Percentages of opinion leadership (yes vs. no) by vaccine uptake and importance.
| Outcome | Non-Opinion Leader | Opinion Leader | |
|---|---|---|---|
|
| |||
| MenACWY | 24.7% (111) | 38.6% (27) | 0.01 * |
| MenB | 14.4% (65) | 34.3% (24) | < 0.01 * |
|
| |||
| HPV | 64.4% (290) | 77.1% (54) | 0.04 * |
| MenACWY | 54.9% (247) | 75.7% (53) | < 0.01 * |
| MenB | 54.9% (247) | 71.4% (50) | <0.01 * |
| HAV | 83.8% (377) | 87.1% (61) | 0.47 |
| HBV | 86.7% (390) | 95.7% (67) | 0.03 * |
| Flu | 63.6% (286) | 64.3% (45) | 0.91 |
| Hib | 42.0% (189) | 54.3% (38) | 0.05 * |
| MMR | 74.4% (335) | 82.9% (58) | 0.13 |
| Td/Tdap | 80.4% (362) | 87.1% (61) | 0.18 |
| Varicella | 70.7% (318) | 65.7% (46) | 0.40 |
| Zoster | 67.1% (302) | 74.3% (52) | 0.23 |
| PCV13 | 41.1% (185) | 58.6% (41) | < 0.01 * |
| PPSV23 | 38.7% (174) | 58.6% (41) | < 0.01 * |
| Average VCI a | 38.4 | 43.0 | <0.01 * |
* Value significant at α = 0.05 level; a 2 sample t-test was performed.
Multivariable logistic regression for opinion leadership membership.
| Outcome | aOR | 95% CI | |
|---|---|---|---|
| HIV status (ref = negative) | 1.69 | (0.82, 3.58) | 0.16 |
| Race (ref = White) | |||
| Black | 2.59 | (1.15, 5.80) | 0.02 * |
| Hispanic | 1.22 | (0.59, 2.50) | 0.59 |
| Other | 2.91 | (1.39, 6.13) | <0.01 * |
| Any STI (ref = No) | 2.02 | (1.14, 3.58) | 0.02 * |
| Other Drug Use (ref = No) | 1.35 | (0.78, 2.33) | 0.28 |
| Multivitamin Use (ref = No) | 1.54 | (0.89, 2.67) | 0.13 |
| High Income (ref = ≤$20,000/year) | 2.36 | (1.06, 5.28) | 0.04 * |
* Value significant at α = 0.05 level; Ref = reference group.
Multivariable logistic regression models for opinion leadership membership by vaccine outcome.
| Outcome | OR | 95% CI | aOR a | 95% CI | ||
|---|---|---|---|---|---|---|
| Vaccination Uptake | ||||||
| MenACWY | 1.92 | (1.13, 3.25) |
|
| (1.11, 3.40) |
|
| MenB | 3.09 | (1.77, 5.41) |
|
| (1.653, 5.34) |
|
| Vaccination Importance | ||||||
| HPV | 1.86 | (1.03, 3.36) |
|
| (1.02, 3.45) |
|
| MenACWY | 2.56 | (1.44, 4.56) |
|
| (1.28, 4.23) |
|
| MenB | 2.06 | (1.18, 3.56) |
|
| (1.03, 3.27) |
|
| HAV | 1.31 | (0.62, 2.76) |
|
| (0.55, 2.57) |
|
| HBV | 3.44 | (1.05, 11.3) |
|
| (0.99, 11.12) |
|
| Flu | 1.03 | (0.61, 1.75) |
|
| (0.55, 1.6) |
|
| Hib | 1.64 | (0.99, 2.72) |
|
| (1.01, 2.95) |
|
| MMR | 1.66 | (0.86, 3.20) |
|
| (0.81, 3.09) |
|
| Td/Tdap | 1.65 | (0.79, 3.45) |
|
| (0.71, 3.21) |
|
| Varicella | 0.80 | (0.47, 1.36) |
|
| (0.44, 1.34) |
|
| Zoster | 1.42 | (0.80, 2.51) |
|
| (0.78, 2.57) |
|
| PCV13 | 2.03 | (1.22, 3.38) |
|
| (1.06, 3.05) |
|
| PPSV23 | 2.24 | (1.34, 3.74) |
|
| (1.16, 3.34) |
|
* Value significant at α = 0.05 level; a Controlling for covariates significant at α = 0.05 at bivariate level: race/ethnicity, STI history, income.